Contact Us
Drug Search Results
More Filters [+]

Isavuconazole

Alternative Names: isavuconazole
Latest Update: 2024-07-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CYP3A4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Cyprus | Czech | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Isavuconazole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Invasive Fungal Infections|Lung Transplant

Phase 3: Candidemia|Candidiasis, Invasive|Aspergillosis|Invasive Fungal Infections|Invasive Pulmonary Aspergillosis|Coronavirus Infections|Severe Acute Respiratory Syndrome|Acute Myeloid Leukemia

Phase 2: Invasive Pulmonary Aspergillosis|Neutropenia|Preleukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Aspergillosis|Pulmonary Aspergillosis|Myeloproliferative Disorders

Phase 1: Healthy Volunteers|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ChiCTR2400086245

N/A

Not yet recruiting

Aspergillosis|Mucormycosis

2026-06-30

YJK-001

N/A

Not yet recruiting

Mucormycosis|Aspergillosis

2026-06-30

C3791001

P4

Recruiting

Invasive Fungal Infections

2025-06-27

IA-DUET

P3

Terminated

Aspergillosis

2024-05-01

Recent News Events

Date

Type

Title

05/16/2024

News Article

 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

05/08/2024

PubMed

 Relative Performance of Volume of Distribution Prediction Methods for Lipophilic Drugs with Uncertainty in LogP Value.

04/23/2024

PubMed

 Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.

04/06/2024

PubMed

 Successful treatment of Purpureocillium lilacinum pulmonary infection with isavuconazole: A case report.

03/11/2024

News Article

 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

03/11/2024

News Article

 FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children

01/19/2024

News Article

 Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions